Posted on 02/25/2010 7:28:52 AM PST by John David Powell
The Obama Administration plan to put new generic drugs on the street faster is another example of how Washington healthcare reformers just don’t get it. While it is true that more generic drugs will reduce healthcare costs, it also is true that health risks will increases for many individuals sensitive to even the slightest changes in their medications.
The Obama drug plan imposes $10 billion in fees over ten years on the brand-name pharmaceutical industry, to be parceled out among big drug makers to eliminate the so-called donut hole, or gap, in Medicare prescription drug coverage. The idea is to help patients continue taking their original drugs instead of switching to cheaper generic versions, or going off their meds entirely.
The plan’s second part prohibits pay-for-delay deals, where brand-name drug makers pay generic drug companies to drop patent challenges. Proponents of this idea say pay-for-delay costs Americans up to $3.5 billion each year.
Generic drugs account for more than 70 percent of all prescriptions filled each year in the U.S. at a savings to patients of about $8 billion a year. A different, and insidious, cost to patients comes from the leeway given by the Food and Drug Administration in the manufacture of generic drugs.
The FDA requires a generic drug to be the same as the original in dosage, safety, strength, performance, intended use, and the way it’s taken. The rules, however, allow for a 20-percent variation in the active ingredient. In other words, the good stuff may be 80 percent less than, or 20 percent more than, what’s in the real deal. This broad range may work for antibiotics, but it creates nasty reactions among patients with heightened sensitivities to their medications.
Internet discussion boards teem with anecdotal evidence. One person tells how his symptoms went away during the year he took the real drug, but returned after three months on the generic version, forcing him to go back to the original that cost seven times more, but with “tremendous results.”
A mother describes how her 11-year- old son, who takes several generic anti-seizure drugs, received a different generic for one prescription that made him extremely sedated and “drool like a faucet,” which put him at risk for drowning in his own saliva. She calls this another example of why the FDA should tighten its regulations and monitoring of generic drugs.
I don’t have to go to the Internet to know about the dirty little secret of generic drugs. My wife has temporal lobe epilepsy, in addition to being very sensitive to generics. We knew generic over-the-counter drugs may include inactive ingredients that cause bad side effects, but we assumed generic drugs were the same as real ones. We discovered the difference when she received a generic anti-seizure drug because our insurance company wouldn’t pay for the original. The doctor and pharmacist insisted there was no difference, but a quick search of epilepsy forums turned up person after person with horror stories similar to hers.
Doctors and federal agencies many times require more than a patient’s story, which makes you wonder why the people charged with watching out for our health apparently ignore a study by Giuseppe Borheini published in the 2003 issue of Clinical Therapeutics (http://www.ncbi.nlm.nih.gov/pubmed/12860486?dopt=Abstract). Borgheini’s team looked at available data going back to 1975 that compared the effectiveness of brand-name psychoactive drugs and their generic counterparts.
One of Borgheini’s more disturbing discoveries was of a study that showed plasma levels of phenytoin were 31 percent lower after a switch from the original anticonvulsant Dilantin. He also learned that when the FDA investigated the sudden recurrence of seizures on the generic valproic acid substituted for Depakote, it found a difference in how the drug gets to where it supposed to go.
Other data showed statistically significant differences in favor of Valium over the generic diazepam in terms of the body’s absorption and distribution.
Borgheini’s research led him to conclude the FDA’s “ essential-similarity requirement should be extended to include more rigorous analyses of tolerability and efficacy in actual patients as well as in healthy subjects.”
This would mean the FDA would have to reconsider its formula variation requirement, demand realistic trials of different formulations, and make sure the active ingredient in the generic drug delivers its bullet to the same target as the original drug.
The FDA will say, however, that it doesn’t have the resources to guarantee generic drugs do no harm. FDA Commissioner Margaret Hamburg recently told attendees of the annual meeting of the Generic Pharmaceutical Association her agency needs more people to review the 2,000 applications for new generic drugs, a number that’s doubled in five years.
Her plan is not to take more time to ensure a generic drug doesn’t harm the patient. No, her plan is to charge generic manufacturers an application fee that will fund additional staff to push out more potentially harmful drugs as part of the Obama Administration’s effort to make medication affordable to everyone, regardless of the cost to health.
John David Powell is an award-winning columnist and writer. His email address is johndavidpowell@yahoo.com
My wife has had these kind of nasty reactions to generics while the original formulations work just find with no such reactions.
Some generics don’t work as well, or the body doesn’t absorb it as well, or they have side affects from the different fillers that their labs use to make them, and they don’t always come in as many strengths. Synthroid is one of those drugs. Name brand works well, generic has some nasty side affects, hair loss and mouth ulcers and isn’t absorbed by the body as well...you need to be tested 3-4 times a year instead of 2 with the name brand. Drives up the cost of health care for those of us on Synthroid.
SET THEIR LOCAL AND DC LINES ON FIRE!
Sen Scott Brown's number is 202-224-4543
Capitol Hill switchboard is 202-224-3121
Lots of local demwit phone numbers on this thread.
http://www.freerepublic.com/focus/news/2408217/posts
Rename, repackage, rewrite it a tad smaller, and sell another pig in a poke.
Tennessee has joined several other states in trying to pass a Health Care Freedom Act. NO COLAs for granny, retired Military or retired fed employees. BIG NEW fees for Tricare for Life retired over 65 Military's secondary health ins. (DOD bill already passed, delayed but goes into effect 2011)
http://www.navytimes.com/news/2009/10/military_tricarefees_blocked_100709w/
New Dem mantra: Woof, woof eat dog food granny....ala let them eat cake.
Friday, February 19, 2010
Obama says slight fix will extend Social Security
http://townhall.com/news/us/2010/02/19/obama_says_slight_fix_will_extend_social_security
Health Care Rationing for Seniors Another Problem in New Obama Plan
http://www.lifenews.com/bio3058.html
TRI CARE FOR LIFE This from a google search:
http://economicspolitics.blogspot.com/2009/05/tricare-for-life-is-obama-trying-to.html
This option would help reduce the costs of TFL, as well as costs for Medicare, by introducing minimum out-of pocket requirements for beneficiaries. Under this option, TFL would not cover any of the first $525 of an enrollee’s cost-sharing liabilities for calendar year 2011 and would limit coverage to 50 percent of the next $4,725 in Medicare cost sharing that the beneficiary incurred. (Because all further cost sharing would be covered by TFL, enrollees could not pay more than $2,888 in cost sharing in that year.)
http://www.cbo.gov/ftpdocs/99xx/doc9925/12-18-HealthOptions.pdf
http://www.vawatchdog.org/09/hcva09/hcva110609-1.htm
Bill Would Restrict Veterans’ Health Care Options 11/06/09
Buyer and McKeon Offer Amendments to Protect Veterans and TRICARE Beneficiaries
Congress plans to block Tricare fee increases
http://www.armytimes.com/news/2009/10/military_tricarefees_blocked_100709w
By Rick Maze - Staff writer, Oct 7, 2009
Tricare fee increases imposed last week by the Defense Department will be repealed by a provision of the compromise 2010 defense authorization bill unveiled Wednesday by House and Senate negotiators.
Snip
The fee increases were announced on Sept. 30 and took effect on Oct. 1, but the defense bill, HR 2647, includes a provision barring any fee increases until the start of fiscal 2011.
Snip
Retired Army Maj. Gen. Bill Matz, president of the National Association for Uniformed Services, said the announcement of fee increases was shocking considering that the Obama administration promised earlier this year to hold off on any new fee Tricare fee increases until fiscal 2011.
“President Obama and DoD assured NAUS and the entire military family earlier this year that there would rightly be no increases in any Tricare fees” in fiscal 2010, Matz said. “We took them at their word, and I can’t believe that a co-pay increase like this was allowed to go forward,” he added.
Bambi doesn't keep his promises...so buyer beware.
The mind of the left. Impose fees on profitable, necessary industries. After all, they can AFFORD IT!! Then control PRICES! And after these companies have been driven out of business, Big Brother can take over!! Imagine Rahm in charge of finding the next chemo drug!!
We’ve experienced differences in how family members react to generics. It’s very obvious with some antibiotics and acne medications. We’ve seen our son’s skin deteriorate dramatically in just a few days when his medication was changed to a generic or from one generic to another. His dermatologist said she’d noticed that when branded Accutane was taken off the market, more of her patients seemed to flare up when they took generic versions. Our son had a lot of trouble with that, but unfortunately, branded medicine is no longer available. (lawsuits got too expensive).
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.